Place of magistral preparations to continue the treatment if the drug is commercially stopped worldwide? A case report of a 10-year-old child with subacute sclerosing panencephalitis (SSPE) requiring inosiplex.

Autor:	Le Cras R; Pharmacy Department, Grenoble University Hospital, Grenoble, France., Mazet R; Pharmacy Department, Grenoble University Hospital, Grenoble, France., Dubois-Teklali F; Pediatric Neurology Unit, Grenoble University Hospital, Grenoble, France., Sabourdy C; Neurology Unit, Grenoble University Hospital, Grenoble, France., Chanoine S; Pharmacy Department, Grenoble University Hospital, Grenoble, France.; Université Grenoble Alpes TIMC, CNRS UMR 5525, Grenoble, France., Lehmann A; Pharmacy Department, Grenoble University Hospital, Grenoble, France., Morin A; Pharmacy Department, Grenoble University Hospital, Grenoble, France., Leenhardt J; Pharmacy Department, Grenoble University Hospital, Grenoble, France.; Université Grenoble Alpes, INSERM, LRB, Grenoble, France., Durand M; Pharmacy Department, Grenoble University Hospital, Grenoble, France., Desruet MD; Pharmacy Department, Grenoble University Hospital, Grenoble, France., Bedouch P; Pharmacy Department, Grenoble University Hospital, Grenoble, France.; Université Grenoble Alpes TIMC, CNRS UMR 5525, Grenoble, France.
Jazyk:	angličtina
Zdroj:	Emerging microbes & infections [Emerg Microbes Infect] 2023 Dec; Vol. 12 (1), pp. 2148563.
DOI:	10.1080/22221751.2022.2148563
Abstrakt:	Subacute sclerosing panencephalitis (SSPE) is a late-onset and fatal viral disease caused by persistent infection of the central nervous system by measles virus (MeV). We present the case of a 10-year-old child from South Asia affected by SSPE, stabilized with a combination of intrathecal interferon-α2b (INF-α2b) injections and oral inosiplex and how we continued the treatment when inosiplex was commercially stopped worldwide.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu